MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
+0.010
+0.33%
Closed 16:00 09/24 EDT
OPEN
3.030
PREV CLOSE
3.040
HIGH
3.100
LOW
2.970
VOLUME
65.99K
TURNOVER
--
52 WEEK HIGH
6.25
52 WEEK LOW
2.150
MARKET CAP
76.51M
P/E (TTM)
-2.0101
1D
5D
1M
3M
1Y
5Y
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
Zacks.com · 08/24 16:03
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
Benzinga · 08/19 15:49
BRIEF-Galmed Pharmaceuticals Ltd - Publication In " Journal Of Autoimmunity" For Its Anti-Inflammatory Compound, Amilo-5Mer
reuters.com · 08/19 12:20
Galmed Pharmaceuticals Announces Publication In "The Journal of Autoimmunity" For Its IND Ready, Amilo-5MER
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The
Benzinga · 08/19 12:14
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its IND ready compound, Ami...
PR Newswire · 08/19 12:00
BRIEF-MHRA Agrees With Galmed's Plan To Use Aramchol Meglumine In Part Of Phase 3 Study
reuters.com · 08/16 12:07
MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the Medicines and Healthcare products Regulatory Agency (MHRA), the pharm...
PR Newswire · 08/16 12:00
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Zacks · 08/11 16:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLMD. Analyze the recent business situations of Galmed Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLMD stock price target is 17.00 with a high estimate of 25.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 5.97M
% Owned: 23.82%
Shares Outstanding: 25.08M
TypeInstitutionsShares
Increased
3
69.88K
New
3
62.88K
Decreased
9
603.41K
Sold Out
8
378.53K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
Allen Baharaff
Chief Financial Officer
Yohai Stenzler
Chief Operating Officer
Guy Nehemya
Chief Scientific Officer
Liat Hayardeny
Lead Director/Independent Director
David Sidransky
Director
Marshall Heinberg
Independent Director
Carol Brosgart
Independent Director
Shmuel Nir
Independent Director
Amir Poshinski
No Data
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.